Patents Represented by Attorney, Agent or Law Firm Felissa H. Cagan
-
Patent number: 5573776Abstract: An osmotic device (10) for delivering an ergot alkaloid into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for extended periods of time. The device (10) comprises a wall (12) surrounding a compartment (13) housing a layer of an ergot alkaloid (14) and a layer (16) of a fluid swellable, hydrophilic polymer. A passageway (17) in the wall (12) connects the ergot alkaloid (14) with the exterior of the device (10). The wall (12) is permeable to the passage of aqueous biological fluid but substantially impermeable to the passage of the hydrophilic polymer (16). In one embodiment the ergot alkaloid (14) has a different color than the hydrophilic polymer (16). The wall (12) is sufficiently translucent to permit the patient to see the amount of ergot alkaloid (14) remaining to be delivered.Type: GrantFiled: September 8, 1994Date of Patent: November 12, 1996Assignee: ALZA CorporationInventors: Juan M. E. Harrison, Brian L. Barclay, Jerry D. Childers, Jeri D. Wright, Virgil A. Place, Patrick S. Wong
-
Patent number: 5551953Abstract: An electrotransport system (20) for delivering a therapeutic agent (36) through a body surface (40) (eg, skin) of a patient includes a pair of electrodes (34, 38) for contacting the body surface, at least one of which contains the therapeutic agent (36). The system (20) is physically separated into a control unit (22) and a delivery unit (24) connected by a radiated energy signal-based telemetry link. The telemetry link may be radio frequency, ultrasonic, optical, infrared or inductively coupled. Signals from the control unit may be transmitted to the delivery unit by the telemetry link, or vice versa. The delivery unit may control electrotransport current on the signal transmitted. The radiated energy signal may be encoded to improve immunity to extrinsic interference. The delivery unit (24) may be configured with sensor means for detecting a condition such as a body or system parameter reaching some predetermined limit.Type: GrantFiled: October 31, 1994Date of Patent: September 3, 1996Assignee: Alza CorporationInventors: Gary A. Lattin, Thomas A. Riddle
-
Patent number: 5545413Abstract: A dosage form is disclosed comprising the antidiabetic drug glipizide for administering to a patient in need of glipizide therapy.Type: GrantFiled: January 22, 1991Date of Patent: August 13, 1996Assignee: Alza CorporationInventors: Anthony L. Kuczynski, Atul D. Ayer, Patrick S. Wong
-
Patent number: 5533972Abstract: A dry-state iontophoretic drug delivery device (10, 30) is provided. The device has drug and electrolyte reservoirs (15, 16) which are initially in a non-hydrated condition. In one embodiment of the invention, a sealed liquid-containing pouch (21, 22) is provided in each electrode assembly (8, 9). Water or other liquid (20) is released from the pouch (21, 22) by pulling a tab (27, 28) attached to a portion (25, 26) of the pouch (21, 22) which is capable of being torn or ripped in order to hydrate the drug and electrolyte reservoirs (15, 16) and activate the device (10, 30). In another embodiment, the device (30) is held in a package (32). The device (30) has pouches (21, 22) which release their liquid contents automatically upon removal of the device (30) from the package (32). In yet another embodiment, the device (40) is held in a package (42) having a compression zone (46). The pouches (21, 22) must be moved through the compression zone (46) when removing the device (40) from the package (42).Type: GrantFiled: September 30, 1993Date of Patent: July 9, 1996Assignee: ALZA CorporationInventors: J. Richard Gyory, John R. Peery
-
Patent number: 5534263Abstract: The present invention is directed to an active agent dosage form which is useful for the prolonged delivery of an active agent formulation to a fluid environment of use. The active agent dosage form is a matrix that has on its surface two or more insoluble bands. The invention is also directed to the method for making the active agent dosage form.Type: GrantFiled: February 24, 1995Date of Patent: July 9, 1996Assignee: Alza CorporationInventors: Patrick S.-L. Wong, David E. Edgren, Liang C. Dong, Vincent J. Ferrari
-
Patent number: 5531736Abstract: The present invention is directed to a fluid-imbibing dispensing device for the initially delayed delivery of an active agent to a fluid environment of use and to a method of using the dispensing device. The dispenser comprises a housing having a first wall section and a second wall section in reversibly sliding telescopic arrangement with each other, which housing maintains its integrity in the environment of use; an internal compartment surrounded and defined by the housing; at least one active agent formulation in the compartment; and expansion means and a push plate in the compartment for separating apart the first and second wall sections of the housing after exposure to the environment of use to expose the active agent formulation to the environment of use.Type: GrantFiled: April 19, 1995Date of Patent: July 2, 1996Assignee: Alza CorporationInventors: Patrick S.-L. Wong, Felix Theeuwes, Steven D. Larsen, Liang C. Dong
-
Patent number: 5532003Abstract: A dosage form is disclosed for delivering pentoxifylline to a patient in need of pentoxifylline therapy. A method is discussed for delivery pentoxifylline to a patient at a dosage form controlled rate over an extended period of time.Type: GrantFiled: January 18, 1994Date of Patent: July 2, 1996Assignee: ALZA CorporationInventors: Patrick S.-L. Wong, George V. Guittard, Atul D. Ayer
-
Patent number: 5529787Abstract: A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.Type: GrantFiled: July 7, 1994Date of Patent: June 25, 1996Assignee: Alza CorporationInventors: Sonya Merrill, Atul D. Ayer, Navjot Chadha, Anthony L. Kuczynski
-
Patent number: 5499979Abstract: A dispenser for use in a fluid environment which is capable of delivery of plurality of drugs in any desired delivery pattern or profile.Type: GrantFiled: March 10, 1994Date of Patent: March 19, 1996Assignee: Alza CorporationInventors: Patrick S.-L. Wong, Felix Theeuwes, James B. Eckenhoff
-
Patent number: 5498255Abstract: The present invention is directed to a fluid-imbibing dispensing device for the extended or protracted delivery of an active agent following an initially delayed startup of the delivery to a fluid environment of use.Type: GrantFiled: May 15, 1995Date of Patent: March 12, 1996Assignee: Alza CorporationInventor: Patrick S.-L. Wong
-
Patent number: 5496266Abstract: A selectively permeable membrane (14) is positioned between the agent reservoir (15) and the electrode (11) of a donor electrode assembly (8) in an iontophoretic delivery device (10). Optionally, an electrolyte reservoir (13) is positioned intermediate the electrode (11) and the agent reservoir (15). In certain embodiments, the membrane (14) is permeable to species of less than a predetermined molecular weight and substantially less permeable to species of greater than the predetermined molecular weight. The agent is capable of dissociating into agent ions and counter ions.Type: GrantFiled: October 27, 1992Date of Patent: March 5, 1996Assignee: ALZA CorporationInventors: Ronald P. Haak, J. Richard Gyory, Felix Theeuwes
-
Patent number: 5489281Abstract: A process for delivering a biocide to a container comprising admitting a biocide delivery device through an exit port of a urine container where the device is sized for passage through the exit port is disclosed.Type: GrantFiled: January 8, 1992Date of Patent: February 6, 1996Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Eun S. Lee, Ivan W. Chin
-
Patent number: 5462741Abstract: A fluid-activated delivery device is disclosed comprising a housing defining an internal compartment, a beneficial agent formulation in the compartment, exit means in the housing for delivering the beneficial agent formulation from the delivery device, and wherein the formulation comprises an active agent in an amount of 50 wt % or greater blended with a glyceride or a mixture of glycerides of a fatty acid.Type: GrantFiled: April 28, 1994Date of Patent: October 31, 1995Assignee: Alza CorporationInventors: John P. Carr, Steven D. Larsen, James B. Eckenhoff
-
Patent number: 5460826Abstract: A bilayer comprising a morphine layer of morphine, poly(alkylene oxide) and poly(vinylpyrrolidone); and an expandable contacting layer of coated granules of a higher molecular weight poly(alkylene oxide) and a hydroxyalkylcellulose, which bilayer is disclosed for morphine therapy. A method is disclosed for using the bilayer composition.Type: GrantFiled: June 27, 1994Date of Patent: October 24, 1995Assignee: Alza CorporationInventors: Sonya Merrill, Atul D. Ayer, Paul Hwang, Anthony L. Kuczynski
-
Patent number: 5443459Abstract: The present invention is directed to a fluid-imbibing dispensing device for the initially delayed delivery of an active agent to a fluid environment of use and to a method of using the dispensing device. The dispenser comprises a housing having a first wall section and a second wall section in reversibly sliding telescopic arrangement with each other, which housing maintains its integrity in the environment of use; an internal compartment surrounded and defined by the housing; at least one active agent formulation in the compartment; and expansion means and a push plate in the compartment for separating apart the first and second wall sections of the housing after exposure to the environment of use to expose the active agent formulation to the environment of use.Type: GrantFiled: August 19, 1993Date of Patent: August 22, 1995Assignee: Alza CorporationInventors: Patrick S. L. Wong, Felix Theeuwes, Steven D. Larsen, Liang C. Dong
-
Patent number: 5417675Abstract: The invention disclosed and claimed an apparatus that relates to a delivery system comprising a biocide, with the delivery system designed and shaped for passages through the exit port of a urine container into the container. The invention disclosed and claim pertains also to a method of preventing infection in a patient by using the apparatus connected to a patient through a catheter.Type: GrantFiled: January 8, 1992Date of Patent: May 23, 1995Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Fun S. Lee, Ivan W. Chin
-
Patent number: 5417676Abstract: An apparatus is disclosed comprising in combination (1) a container for receiving a fluid, and having an exit port, and (2) a delivery system designed for passage through the exit port into the container for releasing a biocide inside the container.Type: GrantFiled: January 8, 1992Date of Patent: May 23, 1995Assignee: Alza CorporationInventors: Tyler Watanabe, Su I. Yum, Eun S. Lee, Ivan W. Chin
-
Patent number: 5417682Abstract: The present invention is directed to a fluid-imbibing dispensing device for the immediate or almost immediate and extended delivery of an active agent over a prolonged period of time together with the initially delayed pulse delivery of an active agent to a fluid environment of use.Type: GrantFiled: January 21, 1994Date of Patent: May 23, 1995Assignee: Alza CorporationInventors: Patrick S. L. Wong, Felix Theeuwes, Steven D. Larsen, Liang C. Dong
-
Patent number: 5413572Abstract: An osmotic system is disclosed for delivering a beneficial agent formulation to an environment of use. The osmotic system comprises (a) an outside semipermeable wall, (b) a middle osmotically active layer, (c) a capsule comprising a beneficial agent, and (d) a passageway for dispensing the beneficial agent from the osmotic system.Type: GrantFiled: February 18, 1994Date of Patent: May 9, 1995Assignee: Alza CorporationInventors: Patrick S. L. Wong, Felix Theeuwes, Brian L. Barclay, Michael H. Dealey
-
Patent number: 5354562Abstract: Solid particle aerosol formulations of polypeptide drugs are made by lyophilizing solutions of the drugs which contain milling stabilizers that inhibit degradation of the drug during subsequent milling. The lyophilized drug is milled in fluid energy mills that have been fitted with abrasion-resistant materials and which use pure nitrogen that has been filtered to eliminate particles of greater than 0.1 .mu.m to transport the drug. The use of (a) milling stabilizers in the solution and (b) abrasion-resistant fluid energy mills that use pure filtered nitrogen in the milling step reduce insoluble contaminants and inactive fractions in the milled product.Type: GrantFiled: February 16, 1993Date of Patent: October 11, 1994Assignee: SRI InternationalInventors: Robert M. Platz, Anna Ip, Clyde L. Whitham